Articles On Immutep (ASX:IMM)

In Short & Caught, Stockhead recaps the ASX stocks that are the most shorted and have had the greatest increase in short interest right now.   How does shorting work? Shorting works by selling stocks you do not actually own in the hope...

Immutep (ASX:IMM) has released new data from the phase 2 lung cancer trial evaluating its lead product candidate eftilagimod alpha in combination with MSD’s anti-PD-1 therapy KEYTRUDA (pembrolizumab) in 114 patients.

ShareCafeEvening Report: 6 June, 2022 by Lauren Evans   The Aussie sharemarket remained in the red for the afternoon session following a weak lead from Wall Street. The Reserve Bank of Australia is set to meet tomorrow, which means investor...

ShareCafeLunch Report: 6 June, 2022 by Melissa Darmawan   The Australian sharemarket has retreated this morning after three weeks of gains ahead of the Reserve Bank of Australia policy meeting tomorrow. Energy is the clear winner while cons...

US FDA approves Clarity Pharma’s IND application Radiopharma-focused biotech, Clarity Pharmaceuticals (ASX: CU6), has announced the approval of its Investigational New Drug (IND) application by the US FDA. The approval was received for Clar...

06 Jun 2022 - A snapshot of the stocks on the move featuring Immutep (ASX:IMM), Liontown Resources (ASX:LTR) & Calidus Resources (ASX:CAI).

Immutep (IMM) publishes new “favourable” data from its first line non-small cell lung cancer (NSCLC) patients of its Phase II TACTI-002 trial The trial is evaluating eftilagimod alpha (efti) when used with collaboration partner MSD’s anti-...

ASX healthcare index finishes another week in the red Enterprise imaging stocks tipped to be a first recovery The goliath battle for fertility company Virtus comes to an end Healthcare and life sciences expert Scott Power – a senior analy...

May. Let’s start with US markets. Because May in the US started with the Dow making its biggest gain since 2020, followed within 24 hours by its biggest loss in 2022, perfectly summing up what kind of month May was to become. The US Fed rai...

The last 30 days have been bright for the Immutep Ltd (ASX: IMM) share price. The biotechnology company’s surge followed two announcements regarding its lead product candidate, efti. At the time of writing, the Immutep share price is 41 ce...

Race Oncology completed dosing stage of Phase, eyes Phase 2 trial Immutep presents trials data at ASCO 2022 meeting Clarity Pharma presents at the Jefferies Biotech Summit Race Oncology (ASX:RAC) has completed the dose escalation stage of...

Immutep (IMM) publishes new interim data from Part A of its second-phase TACTI-002 trial showing “favourable” antitumour activity for its eftilagimod alpha (efti) drug. Data from the trial will be presented in an oral presentation on June...

 ASX to open 1% higher this morning Wall Street surge in a broad based rally overnight April retail sales data to be released today Local shares are poised to open higher this morning following a jump in US stocks overnight. At 8am AEDT,...

ShareCafeImmutep Limited (ASX:IMM) Investor Presentation Immutep Limited (ASX:IMM) Executive Director and CEO Marc Voigt provides an overview of the company, discussing the LAG-3 immune checkpoint, Immutep’s LAG-3 pipeline, eftilagimod alp...

ASX Health stocks endure another topsy-turvy week ending in red Monash IVF makes two key purchases to expand its foothold in fertility sector Actinogen Medical to push ahead with trial into treatment of early Alzheimer’s disease. Healthca...

Immutep (ASX:IMM) has announced the appointment of four new members to its Clinical Advisory Board.

11 May 2022 - A snapshot of stocks in the healthcare sector, including Antisense Therapeutics (ASX:ANP), Kazia Therapeutics (ASX:KZA), and Immutep (ASX:IMM).

Healthcare and life sciences expert Scott Power – a senior analyst with Morgans Financial for 24 years – on what the movers and shakers have been doing in health and which ASX health stocks make Scott’s Powerplays. Are you the cuddly type?...

Biotechnology ASX shares have been one of the biggest victims of persistent inflation and rising interest rate fears over the past 6 months.  The S&P/ASX 300 Pharmaceuticals & Biotechnology (ASX: AXPBKD) has lost about 15% over tha...

Immutep (IMM) sees a significant increase in innate and adaptive immune response biomarkers in its phase IIb AIPAC trial The trial evaluated efti combined with paclitaxel chemotherapy compared to a placebo group in 227 patients with HER2-n...

Immutep’s (IMM) new interim data is selected for presentation at the the world’s largest gathering of oncology professionals New interim data from first line non-small cell lung cancer patients of Immutep’s Phase II trial has been selected...

The Healthcare sector has been struggling as the pandemic wanes But most money managers are still bullish on the sector The biggest movements and news from ASX healthcare stocks this week  Dr Anthony Faucci, America’s top infectious disea...

ShareCafeHow Immutep Treats Head & Neck Cancer   While Immutep boasts development candidates that have been licenced to Novartis AG (SWX: NOVN) in the area of cancer and GlaxoSmithKline plc (GSK; LON: GSK) in the area of autoimmune dis...

The healthcare sector is experiencing a dry run IPO listings have fallen significantly on weak market appetite  A snapshot of the return of recent ASX Healthcare IPO stocks We are currently in the longest and steepest bear market for biot...

Biotech sector has had a tough time recently But there are signs of things improving this year A look at biotech movers on the ASX in the past fortnight Biotech stocks entered a bear phase in the middle of 2021, and things haven’t improve...

Biotechnology company Immutep (IMM) announces new interim data in its treatment of second line metastatic non-small cell lung carcinoma (NSCLC) patients from its Phase 2 TACTI-002 trial Key findings of the trial include a 73.7 per cent of...

The healthcare sector is Australia’s biggest employer, employing 1 in 7 Aussies or roughly two million people. Treasurer Josh Frydenberg announced last night that Australia’s health budget will top $132bn in 2022-23, up from $62bn a decade...

ASX set to rise as US tech stocks rally Sectors that got a big boost from Fed Budget include road and rail infrastructure ($18bn), defence ($15bn), and cybersecurity ($10bn) 5 ASX small caps to watch today: Immutep, Torque Metals, Elsight,...

Highlights Biotechnology companies research living organisms to develop drugs and other products. Investing in biotechnology stocks require due diligence and caution to make a profit and avoid loss. The S&P/ASX 200 Health Care ind...

Immutep (IMM) has recorded new data from second line non-small cell lung cancer (NSCLC) patients from its phase two TACTI-002 study The study is evaluating the combination of efti with Merck & Co’s KEYTRUDA treatment in patients with l...

ASX to open 0.6% lower Commodities bounce back as EU and US to discuss embargo on Russian energy Aussie dollar jumps to US75c ASX to dip, ban on Russian energy imminent Local shares are set to dip this morning after major stock indices on...

Biotech company Immutep (IMM) receives a patent from the Japanese Patent Office for LAG525 The patent is titled “antibody molecules to LAG-3 and uses thereof” and will expire on March 13, 2035 LAG525 is a humanised form of Immutep’s IMP701...

ASX biotech shares have, as a whole, had a remarkably poor run over the last 6 months. Here’s what we mean. Over the past 6 months, the All Ordinaries Index (ASX: XAO) is down 2.2%. Not what you’d like to see. But not close to gut wrenchin...

Immutep (IMM) receives “constructive feedback” from the US Food and Drug Administration (FDA) regarding its clinical development program for eftilagimod alpha (efti) The FDA is supporting Immutep’s view to continue exploring the developme...

ASX to rise as global equities rebound Wall Street and European stocks rebounded strongly overnight after Ukranian President Volodymyr Zelensky said he was open to compromise on some of Russia’s demands to end the war. At the close, all maj...

Telehealth was already a growing space even before the pandemic, but COVID had launched it into the mainstream. At the height of the pandemic in 2020, data from Research and Markets showed that 76% of hospitals in the US were using teleheal...

Ms Turnbull rejoins Immutep’s board having previously served as its chair from October 2010 to November 2017.

ShareCafeBuying Opportunities Beckon Amid Biotech Bloodbath The sharp retreat in global biotech valuations is creating rare buying opportunities as investors flee ‘riskier’ sectors on the back of rising interest rates, dwindling liquidity a...

The ongoing lawsuit involving Johnson & Johnson (J&J)’s talc products took a controversial turn in the courts this week. The healthcare giant is currently staring down 38,000 claims that its talc products (including the famous baby...

Immutep (IMM) is granted a new patent by the Australian Patent Office The claims of the new patent protect Immutep’s intellectual property relating to combined therapeutic preparations, comprising its lead active immunotherapy candidate ef...

Venture capitalist Grant Chamberlain, a partner in Sydney VC OneVentures, has died after falling from a cliff in North Bondi. He was 50. Chamberlain joined OneVentures four years ago following two decades in merchant banking that included m...

With 2021 now officially behind us (at long last!), we asked our Foolish contributors to compile a list of some of the ASX shares experts are saying to buy in January. And, in case you missed it, don’t forget to also check out our coverage...

At the time of writing, the ASX XHJ Healthcare index is up 5.55% over the last five trading days, beating the ASX200 benchmark index which was up 2.8% for the period. Here’s a table showing how ASX-listed healthcare stocks have been perform...

ASX biotech shares were a mixed bag in 2021. Several of the majors came in behind their benchmarks whilst many smaller players outshone the pack. The sector has been the benefactor of long-term tailwinds in diagnostics and demand for nove...

With COVID-19 Omicron surging around the globe, ASX healthcare shares are back in the spotlight. While most don’t deal with the pandemic directly, there are many health and biotechnology companies on the ASX that are plugging away quietly...

It’s been a rocky two weeks for small-cap health companies with 42 gaining ground, 76 losing it, and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. CODE COMPANY PRICE 1 WEEK RETURN %...

The life sciences sector has emerged into the spotlight ever since the pandemic began. In the US, the share prices of major vaccine-producing companies have surged astronomically as COVID-19  ravaged the world. Nasdaq-listed BioNTech, which...

ShareCafeThe Week that Was – December 13-17, 2021 We at ShareCafe understand you are busy and may not have been left with enough time to keep up with the quality content we’ve been bringing you throughout the week. To make it easier to do s...

Immutep (IMM) signs a manufacturing service agreement with Northway Biotech to manufacture its preclinical candidate for autoimmune diseases ahead of clinical testing Northway has already begun developing a manufacturing process for the dr...

The ASX 200 Health Index (XHJ) has dropped by almost 5% at the time of writing, compared to the broader index which is down by 0.20%. Healthcare giant and blood specialist, CSL (ASX:CSL), which makes up a large part of the ASX Healthcare in...